Polyglutamine disease is a class of human neurodegenerative diseases charac
terized by late-onset, progressive neural degeneration. The molecular mecha
nism is expansion, within the coding region of the respective genes, of a C
AG repeat encoding glutamine. The expanded polyglutamine domain confers dom
inant toxicity on the disease protein, leading to neuronal dysfunction and
degeneration. In order to develop Drosophila as a model system to approach
and study such human diseases, a human gene encoding an expanded polyglutam
ine protein was introduced into the fly. Expression of this protein with a
pathogenic polyglutamine domain causes late-onset, progressive degeneration
of cells in the fly, as it does in humans with disease and mouse transgeni
c models. Moreover, the protein shows abnormal protein aggregation in flies
, similar to human disease tissue. These studies indicate that molecular me
chanisms of polyglutamine-induced neurodegeneration are conserved in Drosph
ila. Through these studies and additional studies to develop Ay models for
other human neurodegenerative diseases, including Parkinson's disease, the
power of Drosophila genetics can be brought to bear toward the molecular un
derstanding and treatment of human neurodegeneration. (C) 2001 Elsevier Sci
ence Ltd. All rights reserved.